Alzheimer's Disease
Conditions
Keywords
Mild Cognitive Impairment, Brain Imaging Biomarkers, Magnetic resonance imaging biomarker, Positron Emission Tomography
Brief summary
This study will investigate the volume, function and composition of the brain using magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning technology in participants with memory complaints or early signs of Alzheimer's pathology.
Detailed description
After trial initiation, the protocol was amended to extend the single observation time period (6 to 9 months) to two time points (6 and 12 months), and to focus on prodromal AD (Mini-Mental State Examination \[MMSE\] 23-30 inclusive, Free and Cued Selective Reminding Test \[FCSRT\] less than or equal to \[≤\] 24 for free recall or ≤ 44 for total recall). Participants enrolled under the original protocol were allowed to continue in the extension study if they so desired, and if they met the new inclusion criteria. Due to the number of participants that completed the extended trial, no sub-group analysis was performed based on which amendment the participants entered under.
Interventions
OTHERPET scan using florbetapir
A single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.
OTHERMRI Scan
Three different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.
Sponsors
Eli Lilly and Company
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Present with prodromal Alzheimer's Disease (AD) or mild AD based on the disease diagnostic criteria * Are men or post-menopausal women, at least 55 years of age. Post-menopausal women are defined as women who have had a hysterectomy and/or bilateral oophorectomy; or who have been amenorrheic for at least 2 years * Have a caretaker/study informant who provides a separate written informed consent to participate. If a caretaker/study informant cannot continue, one replacement is allowed * Gradual and progressive change in memory function reported by participants or informants over more than 6 months * Objective evidence of significantly impaired episodic memory characteristic of hippocampal dysfunction on testing: Free and Cued Selective Reminding Test (FCSRT): less than or equal to (≤) 16 for free recall or ≤ 40 for total recall. Protocol amendment: FCSRT ≤ 24 for free recall or ≤ 44 for total recall * Clinical Dementia Rating (CDR) equals 0.5 or 1, Memory box score greater than or equal to 0.5 * Mini Mental Scale Examination (MMSE) 20-30. Protocol amendment: MMSE 23-30, inclusive * Positive florbetapir F 18 scan * Participants must meet all of the Disease Diagnostic Criteria to be considered for enrollment
Exclusion criteria
* Diagnosis or history of other possible etiology of dementia, including but not limited to other neurodegenerative disorders * Frontotemporal dementia, Lewy body disease, vascular dementia, Huntington's Disease or concomitant Parkinson's disease, progressive supranuclear palsy (PSNP) or other movement disorder * Has B12 \<200 pg/L or folate \<7.5 nmol/L indicating vitamin deficiency * Has a history within the past 5 years of a serious infectious disease affecting the brain, including meningitis, or encephalitis * Significant history of alcoholism or substance abuse (at the judgment of the investigator) * Severe or recurrent head injury that is clinically relevant to the disease under study, (that is, with permanent neurological/cognitive sequelae) * Onset of dementia following heart surgery or cardiac arrest * Diagnosis or history of cerebrovascular disease (for example, stroke, transient ischemic attack), severe carotid stenosis, cerebral hemorrhage, intracranial tumor, subarachnoid hemorrhage, or subdural hematoma that could contribute to the subject's current cognitive or functional status, impair ability to fully participate in the trial or that may impact status * Has had a Positron Emission Tomography (PET) within 6 months of the scheduled imaging follow-up * Greater than 4 cerebral microhemorrhages (CMH) on T2\* -weighted gradient-recalled echo sequences (regardless of their anatomical or diagnostic characterization as possible or definite), a single area of superficial siderosis, or prior evidence of macrohemorrhage * Any indications of severe deep white matter lesions or vasogenic edema that present as hyperintense regions on the Fluid Attenuated Inversion Recovery (FLAIR) sequence, or other clinically relevant findings observed on the Magnetic Resonance Imaging (MRI) scans * Specific exclusionary brain MRI findings, as determined by the investigator in consultation with the sponsor, that could either contribute to the participant's current cognitive or functional decline impair ability to fully participate in the trial or that may impact status during the trial (for example, brain tumors or other non-vascular structural abnormalities like hydrocephalus) * History within the past 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen (PSA) post resection * History of clinically significant cardiovascular or renal events * Diastolic blood pressure of 95 or more and systolic blood pressure of 160 or more in sitting position after at least 5 minutes of rest * Any history of seizure * History of clinically significant head trauma or clinically significant unexplained loss of consciousness within the last 5 years (as determined by the investigator in consultation with the Sponsor) * A current Axis I diagnosis of major depressive disorder or other psychiatric illness (Diagnostic and Statistical Manual Revised Fourth Edition \[DSM-IV-TR\]) criteria per the investigator's judgment. (Note: Participants on a stable antidepressant and/or anxiolytic treatment may participate.) * Having suicidal ideations, or attempted suicide in the past 15 years * History of schizophrenia, bipolar disorder, or other severe mental illness * Known history of alcohol or drug abuse (as defined by the DSM-IV-TR) within 5 years prior to enrolling or a positive result regarding use of illicit drugs on the drug screening test * Chronic hepatic diseases as indicated by liver function test abnormalities (alanine trasaminase \[ALT\], aspartate transaminase \[AST\], bilirubin, or gamma-glutamyl transferase \[GGT\] above 2 times upper limit of normal), positive serology for Hepatitis B or C, or other manifestations of liver disease * Has compromised renal function at screening, as determined by creatinine clearance \<30 mL/min based on Cockcroft-Gault calculation of creatinine clearance * History of asthma, chronic obstructive pulmonary disease, or other chronic respiratory conditions * Known positive human immunodeficiency virus (HIV) status, history of syphilitic infection * A clinically significant abnormality in the 12-lead electrocardiograms (ECG), including complete heart block, bradycardia (heart rate \<50 beats/minute), tachycardia (heart rate ≥95 beats/minute), sinus pauses \>2 seconds, second or third degree heart block, QTc \>450 msec for males or QTc \>470 for females * Treatment with an investigational small molecule within 1 year preceding the first study period, or participation in a trial with active or passive immunization against amyloid if participant was assigned to the active treatment arm * Fulfillment of any contraindications to a 3T magnetic resonance imaging (MRI) scan (for example, subjects with non-removable ferromagnetic implants (such as cardiac pacemaker), aneurysm clips or other foreign bodies, or subjects with claustrophobic symptoms that would contraindicate an MRI scan) * Sensitivity to florbetapir F 18 * Are not capable of swallowing whole oral medications * Abnormal thyroid function * Thyroid stimulating hormone (TSH) values are outside of the normal range 0.3-5.6 mIU/L. (NOTE: Participants with stable treatment of hypothyroidism and with normal value of TSH will be allowed to enter the study)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI) | Baseline, 6 Mos; Baseline, 12 Mos | BBSI and VBSI were calculated based on the voxel-wise difference between co-registered baseline and follow-up scans. Least squares (LS) mean value was controlled for baseline value and visit. |
| Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg) | Baseline, 6 Mos; Baseline, 12 Mos | Automated hippocampal volumetry was performed using the Learning Embeddings for Atlas Propagation (LEAP) algorithm. LS mean value was controlled for baseline value and visit. |
| Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | Baseline, 6 Mos; Baseline, 12 Mos | Distributed functional connectivity in selected brain networks was calculated from the rsfMRI scans. Values were derived from low-frequency (0.01-0.1 hertz \[Hz\]) temporal correlations between different regions over the approximately 6-minute rsfMRI time series scan. Distributed measures of functional connectivity were calculated as the mean Pearson correlation between the average low-frequency time courses in predefined sets of regions of interest (ROI) within the default mode network (DMN), salience network (SN) and sensorimotor networks (SMN). LS mean value was controlled for baseline value and visit. |
| Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Baseline, 6 Mos; Baseline, 12 Mos | DTI scans used FA to measure water diffusion directionality in selected white matter (WM) tracts. ROI: Corpus collosum (CC), internal capsule (IC), posterior cingulum bundle (PCB), temporal white matter (TWM), uncinate fasciculus (UF), superior longitudinal fasciculus (SLF). LS mean value was controlled for baseline value and visit. |
| Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Baseline, 6 Mos; Baseline, 12 Mos | DTI scans used MD to measure the overall magnitude of water diffusion in selected WM tracts, without specific regard to directionality. ROI: CC, IC, PCB, TWM, UF, SLF. LS mean value was controlled for baseline value and visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Baseline Brain Amyloid Load Using Positron Emission Tomography (PET) and Florbetapir | Baseline | Composite summary standardized uptake value ratio (SUVR) normalized to mean whole cerebellum. Regions used for composite summary were posterior cingulum, anterior cingulum, parietal cortex, lateral temporal cortex and frontal cortex. |
| Change From Baseline in the Clinical Dementia Rating (CDR) Total Score | Baseline, 6 Mos; Baseline, 12 Mos | The CDR is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score ranges from 0 to 18. Higher scores indicate greater disease severity. LS mean value was controlled for baseline value and visit. |
| Number of Participants With Vasogenic Edema on MRI Scan at a Field Strength of 3 Tesla (3T) | Baseline | — |
| Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T | Baseline, 6 Mos; Baseline, 12 Mos | — |
| Change From Baseline in the Mini Mental State Examination (MMSE) Total Score | Baseline, 6 Mos; Baseline, 12 Mos | The MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS mean value was controlled for baseline value and visit. |
| Change From Baseline in the Alzheimer's Disease Assessment Scale Extended Cognitive Subscale (ADAS-Cog14) Total Score | Baseline, 6 Mos; Baseline, 12 Mos | The ADAS-Cog14 is the ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. LS mean value was controlled for baseline value and visit. |
Countries
France
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Standard of Care Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq \[7 to 10 mCi\] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered. | 56 |
| Total | 56 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Amendment Discontinuation Criteria | 4 |
| Overall Study | Withdrawal by Subject | 11 |
Baseline characteristics
| Characteristic | Standard of Care |
|---|---|
| Age, Continuous | 73.2 years STANDARD_DEVIATION 7.7 |
| Region of Enrollment France | 56 Participants |
| Sex: Female, Male Female | 22 Participants |
| Sex: Female, Male Male | 34 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 10 / 56 |
| serious Total, serious adverse events | 1 / 56 |
Outcome results
Primary
Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA)
DTI scans used FA to measure water diffusion directionality in selected white matter (WM) tracts. ROI: Corpus collosum (CC), internal capsule (IC), posterior cingulum bundle (PCB), temporal white matter (TWM), uncinate fasciculus (UF), superior longitudinal fasciculus (SLF). LS mean value was controlled for baseline value and visit.
Time frame: Baseline, 6 Mos; Baseline, 12 Mos
Population: All participants who enrolled in the study and had an evaluable MRI at the designated time point.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, CC (Genu) - 6 Mos | -0.024 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, CC (Genu) - 12 Mos | -0.021 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, CC (Splenium) - 6 Mos | -0.016 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, CC (Splenium) - 12 Mos | 0.009 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, IC (Left) - 6 Mos | -0.043 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, IC (Left) - 12 Mos | -0.020 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, IC (Right) - 6 Mos | -0.046 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, IC (Right) - 12 Mos | -0.020 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, PCB (Left) - 6 Mos | 0.000 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, PCB (Left) - 12 Mos | 0.010 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, PCB (Right) - 6 Mos | 0.010 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, PCB (Right) - 12 Mos | 0.003 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, TWM (Left) - 6 Mos | -0.017 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, TWM (Left) - 12 Mos | -0.011 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, TWM (Right) - 6 Mos | -0.014 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, TWM (Right) - 12 Mos | -0.009 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, UF (Left) - 6 Mos | -0.027 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, UF (Left) - 12 Mos | 0.010 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, UF (Right) - 6 Mos | -0.032 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, UF (Right) - 12 Mos | 0.005 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, SLF (Left) - 6 Mos | -0.014 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, SLF (Left) - 12 Mos | -0.003 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, SLF (Right) - 6 Mos | -0.006 au |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA) | Mean FA, SLF (Right) - 12 Mos | 0.002 au |
Primary
Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD)
DTI scans used MD to measure the overall magnitude of water diffusion in selected WM tracts, without specific regard to directionality. ROI: CC, IC, PCB, TWM, UF, SLF. LS mean value was controlled for baseline value and visit.
Time frame: Baseline, 6 Mos; Baseline, 12 Mos
Population: All participants who enrolled in the study and had an evaluable MRI at the designated time point.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, CC (Genu) - 6 Mos | 0.201 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, CC (Genu) - 12 Mos | 0.761 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, CC (Splenium) - 6 Mos | 0.663 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, CC (Splenium) - 12 Mos | -0.519 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, IC (Left) - 6 Mos | 0.410 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, IC (Left) - 12 Mos | 0.164 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, IC (Right) - 6 Mos | 0.441 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, IC (Right) - 12 Mos | 0.280 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, PCB (Left) - 6 Mos | -0.062 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, PCB (Left) - 12 Mos | 0.175 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, PCB (Right) - 6 Mos | 0.114 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, PCB (Right) - 12 Mos | 0.297 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD TWM (Left) - 6 Mos | -0.014 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD TWM (Left) - 12 Mos | -0.010 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD TWM (Right) - 6 Mos | 0.243 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD TWM (Right) - 12 Mos | 0.285 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, UF (Left) - 6 Mos | -0.150 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, UF (Left) - 12 Mos | -0.600 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, UF (Right) - 6 Mos | 0.240 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD, UF (Right) - 12 Mos | -0.289 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD SLF (Left) - 6 Mos | 0.083 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD SLF (Left) - 12 Mos | -0.007 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD SLF (Right) - 6 Mos | 0.085 square meters per second (m²/sec) * 10¹⁰ |
| Standard of Care | Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD) | Mean MD SLF (Right) - 12 Mos | 0.097 square meters per second (m²/sec) * 10¹⁰ |
Primary
Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI)
Distributed functional connectivity in selected brain networks was calculated from the rsfMRI scans. Values were derived from low-frequency (0.01-0.1 hertz \[Hz\]) temporal correlations between different regions over the approximately 6-minute rsfMRI time series scan. Distributed measures of functional connectivity were calculated as the mean Pearson correlation between the average low-frequency time courses in predefined sets of regions of interest (ROI) within the default mode network (DMN), salience network (SN) and sensorimotor networks (SMN). LS mean value was controlled for baseline value and visit.
Time frame: Baseline, 6 Mos; Baseline, 12 Mos
Population: All participants who enrolled in the study and had an evaluable MRI at the designated time point.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | Anterior DMN - 6 Mos | 0.017 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | Anterior DMN - 12 Mos | 0.031 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | Anterior SN - 6 Mos | -0.012 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | Anterior SN -12 Mos | -0.025 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | DMN - 6 Mos | -0.029 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | DMN - 12 Mos | -0.031 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | Posterior DMN - 6 Mos | -0.061 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | Posterior DMN - 12 Mos | -0.058 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | Posterior SN - 6 Mos | -0.012 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | Posterior SN - 12 Mos | 0.001 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | SN - 6 Mos | -0.021 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | SN - 12 Mos | -0.008 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | SMN - 6 Mos | 0.041 arbitrary units (au) |
| Standard of Care | Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI) | SMN - 12 Mos | -0.013 arbitrary units (au) |
Primary
Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI)
BBSI and VBSI were calculated based on the voxel-wise difference between co-registered baseline and follow-up scans. Least squares (LS) mean value was controlled for baseline value and visit.
Time frame: Baseline, 6 Mos; Baseline, 12 Mos
Population: All participants who enrolled in the study and had an evaluable MRI at the designated time point.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Standard of Care | Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI) | BBSI - 6 Mos | 6.349 milliliters (mL) |
| Standard of Care | Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI) | BBSI - 12 Mos | 11.663 milliliters (mL) |
| Standard of Care | Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI) | VBSI - 6 Mos | 2.016 milliliters (mL) |
| Standard of Care | Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI) | VBSI - 12 Mos | 4.196 milliliters (mL) |
Primary
Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg)
Automated hippocampal volumetry was performed using the Learning Embeddings for Atlas Propagation (LEAP) algorithm. LS mean value was controlled for baseline value and visit.
Time frame: Baseline, 6 Mos; Baseline, 12 Mos
Population: All participants who enrolled in the study and had an evaluable MRI at the designated time point.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Standard of Care | Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg) | Hippocampus Volume Average % Chg - 6 Mos | -1.693 percentage of hippocampus volume average |
| Standard of Care | Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg) | Hippocampus Volume Average % Chg - 12 Mos | -3.057 percentage of hippocampus volume average |
Secondary
Baseline Brain Amyloid Load Using Positron Emission Tomography (PET) and Florbetapir
Composite summary standardized uptake value ratio (SUVR) normalized to mean whole cerebellum. Regions used for composite summary were posterior cingulum, anterior cingulum, parietal cortex, lateral temporal cortex and frontal cortex.
Time frame: Baseline
Population: All participants with an amyloid positive florbetapir F 18 PET scan at baseline.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Standard of Care | Baseline Brain Amyloid Load Using Positron Emission Tomography (PET) and Florbetapir | 1.581 SUVR unit 1 | Standard Deviation 0.2 |
Secondary
Change From Baseline in the Alzheimer's Disease Assessment Scale Extended Cognitive Subscale (ADAS-Cog14) Total Score
The ADAS-Cog14 is the ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. LS mean value was controlled for baseline value and visit.
Time frame: Baseline, 6 Mos; Baseline, 12 Mos
Population: All participants who enrolled in the study and completed the scale at the designated time point.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Standard of Care | Change From Baseline in the Alzheimer's Disease Assessment Scale Extended Cognitive Subscale (ADAS-Cog14) Total Score | 6 Mos | 0.1 units on a scale |
| Standard of Care | Change From Baseline in the Alzheimer's Disease Assessment Scale Extended Cognitive Subscale (ADAS-Cog14) Total Score | 12 Mos | 0.7 units on a scale |
Secondary
Change From Baseline in the Clinical Dementia Rating (CDR) Total Score
The CDR is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score ranges from 0 to 18. Higher scores indicate greater disease severity. LS mean value was controlled for baseline value and visit.
Time frame: Baseline, 6 Mos; Baseline, 12 Mos
Population: All participants who enrolled in the study and completed the scale at the designated time point.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Standard of Care | Change From Baseline in the Clinical Dementia Rating (CDR) Total Score | 6 Mos | 0.1 units on a scale |
| Standard of Care | Change From Baseline in the Clinical Dementia Rating (CDR) Total Score | 12 Mos | 0.1 units on a scale |
Secondary
Change From Baseline in the Mini Mental State Examination (MMSE) Total Score
The MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS mean value was controlled for baseline value and visit.
Time frame: Baseline, 6 Mos; Baseline, 12 Mos
Population: All participants who enrolled in the study and completed the scale at the designated time point.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Standard of Care | Change From Baseline in the Mini Mental State Examination (MMSE) Total Score | 6 Mos | -1.2 units on a scale |
| Standard of Care | Change From Baseline in the Mini Mental State Examination (MMSE) Total Score | 12 Mos | -1.8 units on a scale |
Secondary
Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T
Time frame: Baseline, 6 Mos; Baseline, 12 Mos
Population: All participants who enrolled in the study and had an evaluable MRI at the designated time point.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Standard of Care | Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T | Baseline | 16 Participants |
| Standard of Care | Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T | 6 Mos | 12 Participants |
| Standard of Care | Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T | 12 Mos | 9 Participants |
Secondary
Number of Participants With Vasogenic Edema on MRI Scan at a Field Strength of 3 Tesla (3T)
Time frame: Baseline
Population: All participants who had an MRI during screening and were classified as screen failures.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Standard of Care | Number of Participants With Vasogenic Edema on MRI Scan at a Field Strength of 3 Tesla (3T) | 4 Participants |